• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Early versus delayed treatment of relapsed ovarian cancer.

作者信息

Rustin Gordon, van der Burg Maria, Griffin Clare, Qian Wendi, Swart Ann Marie

出版信息

Lancet. 2011 Jan 29;377(9763):380-1. doi: 10.1016/S0140-6736(11)60126-8.

DOI:10.1016/S0140-6736(11)60126-8
PMID:21277438
Abstract
摘要

相似文献

1
Early versus delayed treatment of relapsed ovarian cancer.复发性卵巢癌的早期治疗与延迟治疗
Lancet. 2011 Jan 29;377(9763):380-1. doi: 10.1016/S0140-6736(11)60126-8.
2
Ovarian cancer: relevant therapy, not timing, is paramount.卵巢癌：相关治疗而非治疗时机至关重要。
Lancet. 2010 Oct 2;376(9747):1120-2. doi: 10.1016/S0140-6736(10)61515-2.
3
The value of serum and tissular expression of CA 125 antigen, in evaluation of the response to second line chemotherapy for the relapsed ovarian carcinoma.CA 125抗原的血清及组织表达在评估复发性卵巢癌二线化疗反应中的价值。
Rom J Morphol Embryol. 2005;46(4):329-34.
4
An open-label, single-arm Phase II study of intravenous weekly (Days 1 and 8) topotecan in combination with carboplatin (Day 1) every 21 days as second-line therapy in patients with platinum-sensitive relapsed ovarian cancer.一项开放标签、单臂 II 期研究，评估每周静脉注射（第 1 天和第 8 天）拓扑替康联合卡铂（第 1 天），每 21 天为一线治疗后铂敏感复发性卵巢癌患者的二线治疗。
Gynecol Oncol. 2011 Jan;120(1):38-42. doi: 10.1016/j.ygyno.2010.10.011. Epub 2010 Nov 5.
5
StatBite: Ovarian cancer: risk of recurrence by stage of diagnosis.数据简讯：卵巢癌：根据诊断分期的复发风险
J Natl Cancer Inst. 2009 Sep 16;101(18):1234. doi: 10.1093/jnci/djp308. Epub 2009 Sep 8.
6
The prognostic value of CA-125 in epithelial ovarian cancer patients during and after chemotherapy.CA-125在上皮性卵巢癌患者化疗期间及化疗后的预后价值。
Acta Chir Hung. 1997;36(1-4):213-4.
7
CA-125 response in patients with recurrent ovarian or primary peritoneal cancer treated with pegylated liposomal doxorubicin or topotecan.接受聚乙二醇化脂质体阿霉素或拓扑替康治疗的复发性卵巢癌或原发性腹膜癌患者的CA-125反应
Gynecol Oncol. 2006 Oct;103(1):212-8. doi: 10.1016/j.ygyno.2006.02.026. Epub 2006 May 3.
8
[Profiling of serum tumor markers in patients with epithelial ovarian carcinoma].[上皮性卵巢癌患者血清肿瘤标志物分析]
Zhonghua Fu Chan Ke Za Zhi. 2009 Feb;44(2):121-5.
9
Chemotherapy of ovarian cancer.卵巢癌的化学疗法。
Semin Oncol. 1991 Jun;18(3):222-32.
10
[Decision-making of treatment and relative problems about recurrent and drug-resistant gynecologic neoplasms].
Zhonghua Fu Chan Ke Za Zhi. 2010 Nov;45(11):801-3.

引用本文的文献

1
circ-TFRC downregulation suppresses ovarian cancer progression via miR-615-3p/IGF2 axis regulation.环状转录因子受体下调通过miR-615-3p/胰岛素样生长因子2轴调控抑制卵巢癌进展。
Cancer Cell Int. 2024 Apr 27;24(1):152. doi: 10.1186/s12935-024-03287-4.
2
Long non-coding RNA ADAMTS9-AS1 attenuates ferroptosis by Targeting microRNA-587/solute carrier family 7 member 11 axis in epithelial ovarian cancer.长链非编码 RNA ADAMTS9-AS1 通过靶向 microRNA-587/溶质载体家族 7 成员 11 轴抑制上皮性卵巢癌中的铁死亡。
Bioengineered. 2022 Apr;13(4):8226-8239. doi: 10.1080/21655979.2022.2049470.
3
Circulating Biomarkers for Therapeutic Monitoring of Anti-cancer Agents.
用于抗癌药物治疗监测的循环生物标志物。
Oncologist. 2022 May 6;27(5):352-362. doi: 10.1093/oncolo/oyac047.
4
Adherence to colonoscopy at 1 year following resection of localized colon cancer: a retrospective cohort study.局部结肠癌切除术后1年结肠镜检查的依从性：一项回顾性队列研究。
Therap Adv Gastroenterol. 2018 Mar 26;11:1756284818765920. doi: 10.1177/1756284818765920. eCollection 2018.
5
LncRNA ARAP1-AS1 aggravates the malignant phenotypes of ovarian cancer cells through sponging miR-4735-3p to enhance PLAGL2 expression.长链非编码RNA ARAP1-AS1通过吸附miR-4735-3p增强PLAGL2表达，从而加重卵巢癌细胞的恶性表型。
Cytotechnology. 2021 Jun;73(3):363-372. doi: 10.1007/s10616-021-00463-6. Epub 2021 Apr 3.
6
Downregulation of hsa_circ_0026123 suppresses ovarian cancer cell metastasis and proliferation through the miR‑124‑3p/EZH2 signaling pathway.hsa_circ_0026123 的下调通过 miR-124-3p/EZH2 信号通路抑制卵巢癌细胞转移和增殖。
Int J Mol Med. 2021 Feb;47(2):668-676. doi: 10.3892/ijmm.2020.4804. Epub 2020 Dec 1.
7
LncRNA GClnc1 may contribute to the progression of ovarian cancer by regulating p53 signaling pathway.长链非编码 RNA GClnc1 可能通过调节 p53 信号通路促进卵巢癌的进展。
Eur J Histochem. 2020 Nov 10;64(4):3166. doi: 10.4081/ejh.2020.3166.
8
The Average Time Gap Between CA-125 Tumor Marker Elevation and Confirmation of Recurrence in Epithelial Ovarian Cancer Patients at Princess Noorah Oncology Center, Jeddah, Saudi Arabia.沙特阿拉伯吉达市诺拉公主肿瘤中心上皮性卵巢癌患者CA - 125肿瘤标志物升高与复发确诊之间的平均时间间隔。
Cureus. 2020 Aug 2;12(8):e9518. doi: 10.7759/cureus.9518.
9
Dynamic TF-lncRNA Regulatory Networks Revealed Prognostic Signatures in the Development of Ovarian Cancer.动态TF-lncRNA调控网络揭示卵巢癌发生发展中的预后特征
Front Bioeng Biotechnol. 2020 May 13;8:460. doi: 10.3389/fbioe.2020.00460. eCollection 2020.
10
Clinical significance of RAD51C and its contribution to ovarian carcinogenesis.RAD51C的临床意义及其在卵巢癌发生中的作用。
Int J Clin Exp Pathol. 2020 Jan 1;13(1):14-20. eCollection 2020.